7 research outputs found
A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure
Objective. To evaluate the efficacy and safety of triple fixed-combination bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% (TFC) versus dual fixed-combination brimonidine 0.2%/timolol 0.5% (DFC) in primary open-angle glaucoma and ocular hypertension. Methods. Patients with intraocular pressure (IOP) â„23 and â€34âmmHg were randomized to twice-daily TFC or DFC. The primary variable is the change in worse eye mean IOP from baseline at week 12 (modified intent-to-treat (mITT) population). Secondary endpoints are mean IOP and mean change from baseline at weeks 1, 2, 4, 8, and 12 (mITT population). TFC superiority was demonstrated if the primary variable favored TFC (pâ€0.05). Sensitivity analyses were conducted, and safety was assessed at all visits. Results. TFC (n=93) provided greater IOP reductions from baseline than DFC (n=97) at week 12 (treatment difference, 0.85âmmHg; p=0.028) and all other visits. TFC was also superior to DFC in patients with high baseline IOP (i.e., IOPââ„â25âmmHg; pâ€0.011). Conjunctival hyperemia, ocular irritation, and dry eye were reported more often with TFC (pâ€0.016); however, discontinuations for ocular adverse events were similar between treatments. Conclusions. TFC demonstrated IOP-lowering benefits that outweigh the risk of predominantly mild ocular side effects, which may be particularly relevant in patients who require greater IOP lowering to prevent/delay disease progression. This trial is registered with ClinicalTrials.gov registry number: NCT01241240
Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study
A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG
AIM: To evaluate the long-term response to the fixed combination of dorzolamide/timolol in patients with primary open angle glaucoma (POAG) and the addition of other intraocular pressure (IOP) lowering medications such as prostaglandin analogs and brimonidine.METHODS: A retrospective, non-randomized, and descriptive clinical study was performed with 182 eyes diagnosed with POAG. Patients were divided into three groups:a group with fixed combination of dorzolamide/timolol only, a second group with prostaglandin analogs plus fixed combination of dorzolamide/timolol, and a third group with the addition of brimonidine to the same fixed combination. IOP data were gathered retrospectively and the differences between groups were calculated.RESULTS: IOP was reduced satisfactorily in all three groups; however, a progressive IOP reduction was noted in the group with the fixed combination plus prostaglandin analogs. In this group, a progressive, significant and more homogeneous response of the reduction was noted in comparison with the other groups.CONCLUSION: IOP reduction was efficacious in all three groups. The addition of prostaglandin analogs showed progressive IOP reduction, progressive response and absence of long-term drift. Brimonidine did not show a significant additive effect
Entrampamiento de iris en implante Ex-PRESS liberado por YAG laser. Reporte de un caso
Resumen
Los autores reportan el caso de un paciente femenino de 68 años que cursĂł con hipotonĂa y cĂĄmara plana en el postoperatorio de un implante Ex-PRESS. Tras resolverse el cuadro se observĂł obstrucciĂłn de la luz de entrada del implante por iris, el cuĂĄl fue liberado por medio de YAG laser. Reportamos nuestros resultados y discutimos los casos que se abordaron de manera similar en la literatura.
Â
Abstract
The authors report a case of a 68-year-old woman who developed hypotony and a narrow anterior chamber after an Ex-PRESS shunt implant. After resolution, tube was obstructed by iris hanging to the end of the shunt, which was liberated using Nd:YAG laser. We discuss our results compared with others shown in the literature
A Phase III, Randomized, Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma
<p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s40123-018-0128-8">https://link.springer.com/article/10.1007/s40123-018-0128-8</a></p><p></p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/ĂąÂÂmailto:[email protected]ĂąÂÂ"><b>[email protected]</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as âpeer reviewedâ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>âą Slide decks</p>
<p>âą Videos and animations</p>
<p>âą Audio abstracts</p>
<p>âą Audio slides</p
Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma.
Primary angle closure glaucoma (PACG) is a major cause of blindness worldwide. We conducted a genome-wide association study (GWAS) followed by replication in a combined total of 10,503 PACG cases and 29,567 controls drawn from 24 countries across Asia, Australia, Europe, North America, and South America. We observed significant evidence of disease association at five new genetic loci upon meta-analysis of all patient collections. These loci are at EPDR1 rs3816415 (odds ratio (OR) = 1.24, P = 5.94 Ă 10(-15)), CHAT rs1258267 (OR = 1.22, P = 2.85 Ă 10(-16)), GLIS3 rs736893 (OR = 1.18, P = 1.43 Ă 10(-14)), FERMT2 rs7494379 (OR = 1.14, P = 3.43 Ă 10(-11)), and DPM2-FAM102A rs3739821 (OR = 1.15, P = 8.32 Ă 10(-12)). We also confirmed significant association at three previously described loci (P < 5 Ă 10(-8) for each sentinel SNP at PLEKHA7, COL11A1, and PCMTD1-ST18), providing new insights into the biology of PACG